TEST:

SimpleScreen™ CRC blood test

''Freenome, an early cancer detection company developing blood-based screening tests, welcomes the inclusion of blood-based testing in the American Cancer Society (ACS) Guideline for Colorectal Cancer Screening, marking an important milestone in expanding patient access to non-invasive colorectal cancer screening options. As part of its guideline update, the ACS Guideline Development Group reviewed the available clinical performance and modeling data for blood-based testing, including Freenome’s SimpleScreen™ CRC screening test.''

"Freenome...today announced an exclusive license agreement with Exact Sciences to advance the commercialization of its colorectal (CRC) blood-based screening test,* including the U.S. commercial rights and the underlying technology. Freenome retains the rights for its CRC blood test when it is ordered in combination with additional cancer screening tests, including for lung and more than 10 other initial cancer indications the company is pursuing...Final module for the first version of Freenome’s colorectal cancer test has been submitted to FDA; approval and commercial launch anticipated in 2026"